The FDA has approved amantadine in a new formulation for the dyskinesia in Parkinson’s patients based on a Phase 3 randomized, double-blind, placebo-controlled study reported in JAMA Neurology.
Archives for August 2017
In this 12-minute video for primary care physicians from August 25, 2017, movement disorder specialist Allison Willis, MD, from the University of Pennsylvania explains that “More men than women are diagnosed with Parkinson’s Disease by almost a 2 to 1 margin. … Full Story>
This driving rehabilitation session will discuss the topics of the aging driver and requirements by the California DMV if a driver has had a change in medical status (such as being diagnosed with Parkinson’s Disease), suspended license or let his or her license expire The session will be held at the Stanford Neuroscience Health Center. The program is free but advance registration is required…. Full Story>
Stanford Movement Disorders Center is kicking off a webinar series.
Join us for a free, one-hour webinar on diagnosing progressive supranuclear palsy (PSP), the most common atypical parkinsonism disorder. The speaker is Stanford movement disorders specialist Kathleen Poston, MD. Please spread the word!… Full Story>